Sanofi buys Genzyme for $20 billion

Sanofi-aventis buys biotech Genzyme for $20 billion By Ben Rooney, staff reporter


NEW YORK (CNNMoney) -- Sanofi-aventis said Wednesday that it will buy Genzyme for $20.1 billion in cash, plus payments contingent on the success of some of Genzyme's drugs.

The French pharmaceutical maker said it will pay $74 per share for the Cambridge, Mass.-based biotechnology company. Genzyme (GENZ, Fortune 500) shares closed Tuesday at $74.30 each.

The stock has traded in a range between roughly $72 and $74.50 over the last 52 weeks.

The long-awaited deal, which has received antitrust clearance from regulators in the United States and Europe, is expected to close early in the second quarter of 2011.

Under the terms of the deal, Sanofi (SA) will award each Genzyme shareholder a "contingent value right" -- or CVR -- for each share they own. The CVR, which will eventually be publicly traded, entitles the holder to cash payments if Genzyme drugs reach certain sales "milestones."

Christopher Viehbacher, Sanofi's chief executive, said the CVR served as an "important value bridge" between the two companies, and that it "rewards both Genzyme and Sanofi-aventis shareholders."

The deal consummates a long courtship between the two companies. Sanofi offered to buy Genzyme for $69 per share last year, a bid rejected by Genzyme as too low. Sanofi made an unsolicited offer in August and a hostile takeover bid in October.

"Conclusion of the Sanofi-Genzyme saga is a positive outcome for Sanofi shareholders," analysts at Deutsche Bank wrote in a research note. The deal will raise Sanofi's profile in the United States, and could help it expand into new areas such as cancer treatment, the note read.

The CVR was an important part of the final agreement, said Jim Prutow, a health care industry expert at PRTM, a global management consulting firm.

"Although the deal took time, the Contingent Value Right structure is a win-win, since both Genzyme and Sanofi will benefit if the MS (multiple sclerosis) product is successful," he said.

Genzyme is developing a drug called Lemtrada, which can be used to treat multiple sclerosis and other diseases.

Under the CVR, investors will be paid $1 per share when Lemtrada is approved by the U.S. Food and Drug Administration. It could be worth up to $4 if certain sales targets are achieved.

Prutow said the deal reflects the need for "established" pharmaceutical companies such as Sanofi to build their product pipeline through mergers and acquisitions "due to the lack of new drug approvals."

It also shows that drug companies can still expand their businesses through acquisitions despite increased litigation costs and regulatory hurdles, he added.

Separately, Genzyme reported fourth-quarter earnings that missed analysts' expectations, while sales held firm.

Genzyme said net income in the quarter was $221.1 million, or 82 cents per share, compared with $78.1 million, or 29 cents per share, in the fourth quarter of 2009.

Sales rose 23% to $1.15 billion from a year ago.

Analysts surveyed by Thomson Reuters were expecting 86 cents per share on sales of $1.17 billion.

Shares of Genzyme (GENZ, Fortune 500) were little changed in premarket trading, while U.S.-listed shares of Sanofi (SNY) rose nearly 1.4%. To top of page

Frontline troops push for solar energy
The U.S. Marines are testing renewable energy technologies like solar to reduce costs and casualties associated with fossil fuels. Play
25 Best Places to find rich singles
Looking for Mr. or Ms. Moneybags? Hunt down the perfect mate in these wealthy cities, which are brimming with unattached professionals. More
Fun festivals: Twins to mustard to pirates!
You'll see double in Twinsburg, Ohio, and Ketchup lovers should beware in Middleton, WI. Here's some of the best and strangest town festivals. Play
Index Last Change % Change
Dow 17,104.96 -1.74 -0.01%
Nasdaq 4,564.65 -5.99 -0.13%
S&P 500 1,997.53 -2.49 -0.12%
Treasuries 2.36 -0.03 -1.25%
Data as of 3:19pm ET
Company Price Change % Change
Bank of America Corp... 16.16 -0.16 -1.01%
Apple Inc 102.15 1.26 1.25%
Facebook Inc 74.71 -1.25 -1.65%
Yahoo! Inc 38.20 0.41 1.08%
Pfizer Inc 29.48 0.27 0.91%
Data as of 3:05pm ET

Sections

As Elon Musk cancels the latest launch of a SpaceX rocket, he's also got some "horrible nightmares" to contend with. More

Former Fed chief Ben Bernanke believes the 2008 financial crisis was the worst in global history, topping even the Great Depression. More

Tech fans are already excited about the launch of Apple's iPhone 6 next month. There's now a report suggesting that the iWatch could be coming too. Wall Street is pleased. More

Utah State professor Michael Glauser cycled 4,000 miles this summer, visiting 100 entrepreneurs across the country. Here's a snapshot of how they grew their businesses. More

Mary Fallon, from Durham, Maine, is a mother of three children, two dogs, 25 chickens and a flock of 22 sheep. Here are journal entries from a day in her life. More

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.